All In MedTech

Device Trial Radar · NCT01746589

Visual Outcomes and Contrast Sensitivity After Myopic LASIK

Evaluation Of Visual Outcomes and Contrast Sensitivity After Myopic Wavefront-Optimized Lasik Using the 200 KHZ WAVELIGHT® FS200 Femtosecond Laser and the WAVELIGHT® ALLEGRETTO WAVE® EYE-Q Laser

Last checked: Nov 20, 2026Latest source record: Jan 28, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

22

Actual

Start

Nov 2011

Primary completion

Jan 2012

Study completion Jan 2012

Sponsor

Lead sponsor
Daniel S. Durrie, MDAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Alcon Research
First posted
Dec 11, 2012

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Evaluate visual outcomes and contrast sensitivity for subjects undergoing bilateral myopic LASIK procedure using the 200 kHz WaveLight® FS200 Femtosecond Laser and the WaveLight® Allegretto Wave® Eye-Q Laser. The use of advanced technology may decrease the loss of contrast sensitivity and improvement of postoperative visual acuity results.

Conditions

  • Myopia

Interventions

  • bilateral myopic LASIKDevice

    200 kHz WaveLight® FS200 Femtosecond Laser and the WaveLight® Allegretto Wave® Eye-Q Laser

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Uncorrected Visual Acuity over time postoperativelyTime frame: Postoperatively immediate (1-3 minutes), 30 minutes, 1 hour, 2 hours, 4 hours, 1 day, and 1 month

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Durrie Vision

    Overland Park, Kansas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.